Galderma has announced that Alluzience® has received a positive decision for use in Europe as the first ready-to-use neuromodulator, a wrinkle relaxing injection. Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient. The product’s ready-to-use liquid formulation avoids any calculations and allows for more precision, meaning it has the potential to improve safety and dosing accuracy compared with powder form BoNT-A preparations. The product was developed using novel production technologies meaning it is free from human and animal-derived proteins such as human serum albumin and lactose. Clinical trials demonstrated that patients treated with Alluzience® for wrinkles had a rapid onset of effect starting from day one, with improvements lasting up to six months. The majority of adverse reactions reported with Alluzience® in clinical trials were of mild to moderate intensity and reversible.